What is MTD's House Rating?

MTD scores 50 out of 100 (grade C) as of 2026-10-16, ranking #26 of 150 Health Care stocks we cover.

What do analysts say about MTD?

ThetaGrade's analyst-sentiment pillar for MTD scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.

When does MTD report earnings next?

MTD's next earnings report is estimated for about 2026-11-05 (window 2026-10-29 to 2026-11-12), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.

ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

MTD Mettler Toledo

Health Care · Life Sciences Tools & Services · close $1622.29 (2026-10-16) · latest quarter in EDGAR: 2026-06-30

#26/150 in sector · #191/964 overall

Mettler Toledo (MTD) has a ThetaGrade House Rating of 50/100 (grade C), ranking #26 of 150 in Health Care. Its strongest pillars are profitability (71) and cash flow (63); its weakest is valuation (35). TTM revenue growth is 6.9% and operating margin 28.2%.

Data as of 2026-10-16.

Analyst sentiment

weight 7.5% · 50

Consensus score (1–5) (3.8%)	derived	23
90-day net rating shift (3.8%)	derived	49

Growth

weight 30.83% · 40

Revenue growth YoY (TTM) (12.3%)	6.9%	34
EPS growth YoY (TTM) (12.3%)	12.5%	49
Revenue acceleration (6.2%)	-2.7%	33

Profitability

weight 18.5% · 71

Operating margin (9.9%)	28.2%	85
4Q gross-margin change (8.6%)	0.3%	55

Balance sheet

weight 18.5% · 46

Net debt / EBITDA (9.9%)	1.64×	49
Current ratio (4.9%)	1.12	13
Interest coverage (3.7%)	17.03×	81

Cash flow

weight 12.33% · 63

FCF margin (6.2%)	21.1%	76
FCF yield (6.2%)	2.6%	50

Valuation

weight 12.33% · 35

P/E (inverted) (6.2%)	36.57×	39
EV/Sales (inverted) (6.2%)	8.35×	30

Technicals (EOD)

RSI(14)	71.4
EMA 9 / 21	1582.96 / 1530.17
200-day SMA	1326.89
Volume vs 20d avg	1.19×
20-day return	15.0%

Exit-rule monitor

EXITRating break: House Rating below 60

Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Gross profit: GrossProfit · Operating income: Pretax income + interest expense (EBIT proxy) · Interest expense: InterestExpense · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).

Get rating changes like MTD's in the free Daily Brief

The market’s key events and signals, digested before the open.

✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
✓ OPEX, FOMC, CPI and jobs-day reminders

Free. Want more? See Premium (waitlist).

FAQ

What is MTD's House Rating?: MTD scores 50 out of 100 (grade C) as of 2026-10-16, ranking #26 of 150 Health Care stocks we cover.
What do analysts say about MTD?: ThetaGrade's analyst-sentiment pillar for MTD scores 50/100 against its sector peers, which we read as mixed. This is our own derived score; we do not republish individual analyst ratings, counts or targets.
When does MTD report earnings next?: MTD's next earnings report is estimated for about 2026-11-05 (window 2026-10-29 to 2026-11-12), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
Is MTD a buy?: ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.

Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology